UCB (UCBJF) News Today → Elon Musk’s Controversial New Project: “Apollo” (From InvestorPlace) (Ad) Free UCBJF Stock Alerts $128.73 0.00 (0.00%) (As of 04/23/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineUCB Convening Notice to the General Meeting of the Shareholders 2024finance.yahoo.com - March 22 at 6:29 AMUCB price target raised by EUR 13 at Barclaysrealmoney.thestreet.com - March 7 at 12:37 AMUCB SA reports FY resultsmsn.com - February 28 at 3:28 PMStocks A-Zmarketwatch.com - February 10 at 6:56 PMInvestors growing more bullish on SMID cap biotech stocksmsn.com - February 4 at 5:57 PMUCB launches newly approved psoriasis drug Bimzelx in USmsn.com - November 14 at 6:22 PMPost Hoc Analysis Showed CIMZIA® (Certolizumab Pegol) Resulted in Meaningful Efficacy for RA Patients with High Levels of Rheumatoid Factor (RF)finance.yahoo.com - November 11 at 9:46 AMUCB Presents New Five-Year Data on BIMZELX® (bimekizumab-bkzx) in Ankylosing Spondylitis at ACR Convergence 2023finance.yahoo.com - November 10 at 8:56 AMBIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasisfinance.yahoo.com - October 18 at 8:57 AMUCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravisfinance.yahoo.com - October 18 at 12:21 AMUCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023finance.yahoo.com - October 13 at 1:54 PMPhase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativafinance.yahoo.com - October 12 at 12:42 PMUCB SA (OTCMKTS:UCBJF) Receives Average Rating of "Hold" from Analystsmarketbeat.com - August 14 at 4:28 AMFDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adultsfinance.yahoo.com - June 27 at 6:50 PMChina Anti-Rheumatic Drug Markets Report 2022-2027 Featuring Pfizer, F. Hoffmann-La Roche, UCB S.A., Eli Lilly and Company, & AbbVie Inc.finance.yahoo.com - February 22 at 5:33 PMUCB SA (UCBJF)finance.yahoo.com - October 20 at 4:01 PMUCB SA (OTCMKTS:UCBJF) Given Average Recommendation of "Hold" by Brokeragesmarketbeat.com - September 12 at 6:28 AMUCB (OTCMKTS:UCBJF) Downgraded by Jefferies Financial Groupmarketbeat.com - July 25 at 7:32 AMUCB SA (OTCMKTS:UCBJF) Short Interest Up 31.0% in Aprilmarketbeat.com - May 16 at 6:16 AMHere's Why Momentum in UCB SA (UCBJF) Should Keep goingfinance.yahoo.com - April 25 at 2:16 PMWhat Makes UCB SA (UCBJF) a Good Fit for "Trend Investing"msn.com - March 31 at 10:21 AMUCB SA/NV - CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS 2022finanznachrichten.de - March 25 at 4:58 AMBiogen signs licensing deal with Xbrane for potential biosimilar to Cimziaseekingalpha.com - February 7 at 7:18 PMZGNX Jan 2022 7.000 callfinance.yahoo.com - January 23 at 7:55 PMWhy Zogenix Flew Higher Before Leveling Off This Weekmsn.com - January 21 at 10:26 AMUCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlightsmarkets.businessinsider.com - January 19 at 8:01 AMUCB Showcases Key Rheumatology Data at ACR Convergence 2021finance.yahoo.com - November 5 at 10:20 AMUCB to license its AI technology that improves identification of Osteoporosis to ImageBiopsy Labfinance.yahoo.com - October 20 at 7:33 AMBRIEF-UCB SA Gives An Update On U.S. FDA Review Of Biologics License Application (BLA) For Bimekizumabmsn.com - October 16 at 6:35 PMNew Bimekizumab Two-Year Data in Moderate to Severe Plaque Psoriasis Presented at the 30th European Academy of Dermatology and Venereology Congressfinance.yahoo.com - September 29 at 3:49 PMWhy New Oriental Education Shares Are Fallingbenzinga.com - August 27 at 8:44 PMSpectrumDNA, Inc. (SPXA)finance.yahoo.com - August 12 at 10:35 PM Get UCB News Delivered to You Automatically Sign up to receive the latest news and ratings for UCBJF and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon Musk’s Controversial New Project: “Apollo” (Ad)Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"... Click here to see the details because there's a lot of money at stake. UCBJF Media Mentions By Week UCBJF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UCBJF News Sentiment▼0.000.44▲Average Medical News Sentiment UCBJF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UCBJF Articles This Week▼00▲UCBJF Articles Average Week Get UCB News Delivered to You Automatically Sign up to receive the latest news and ratings for UCBJF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BAYRY News Today CNTX News Today IMUC News Today GNMSF News Today GRFS News Today HYPMY News Today IMVIQ News Today ISCO News Today LVTX News Today MYNZ News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:UCBJF) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UCB SA Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
